An official website of the United States government
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Trial Status: active
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and
Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated
solid tumors.
Inclusion Criteria
18 years of age
Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy
Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors.
ECOG performance status 0 or 1
Adequate organ function
Exclusion Criteria
Primary central nervous system (CNS) tumors
Active brain metastases
Known impairment of GI function that would alter the absorption
Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06128551.
